Clinical observation of adefovir dipivoxil in the treatment of hepatitis B ptients with HBeAg positive / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
; (12): 986-988, 2013.
Article
en Zh
| WPRIM
| ID: wpr-431912
Biblioteca responsable:
WPRO
ABSTRACT
Objective To evaluate the safety and effect of adefovir dipivoxil (ADV) on hepatitis B in HBeAgpositive patients.Methods 131 patients were divided into two groups randomly.Two groups were treated with ADV (10mg/d)and matrine (0.6g/d),respectively.The rate of HBV negative,the normalization rates of ALT,HBeAg loss and anfi-HBe seroconversion were evaluated respectively.Results After 12 weeks of treatment,the rate of HBV negative,the normalization rates of ALT,HBeAg loss and anti-HBe seroconversion of ADV were all significantly higher than those of matrine group(53.2% vs 7.8%,36.0% vs 8.7%,13.6% vs 3.1%,6.2% vs 0,respectively,x2 =56.32,23.18,all P < 0.01).Conclusion The domestic ADV superior to matrine in HBeAg-positive patients.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Primary Medicine and Pharmacy
Año:
2013
Tipo del documento:
Article